# US 2017/0283779 A1 · Bacteriophage engineering methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283779 A1
- Document ID: US20170283779A1
- Status: Published application
- Kind: A1
- Application number: 15/470,685
- Filed: 2017-03-27
- Published: 2017-10-05
- Earliest claimed: 2016-03-28
- Assignees: The Charles Stark Draper Laboratory, Inc.
- Applicants: The Charles Stark Draper Laboratory, Inc.
- Inventors: JASON HOLDER; Connor McBrine; Sarah Gruszka; Miles Rogers; Nicole Billings
- Web page: https://patentgrep.com/patent/US20170283779A1

## CPC

- C12Q 1/70: involving virus or bacteriophage {(immunoassay for viruses G01N33/56983)}
- B01L 3/502753: {characterised by bulk separation arrangements on lab-on-a-chip devices, e.g. for filtration or centrifugation}
- B01L 3/502761: {specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads or physically stretching molecules}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/66: General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
- C12N 15/86: Viral vectors
- C12N 15/902: {using homologous recombination}
- C12Y 301/00: Hydrolases acting on ester bonds (3.1)
- B01L 2200/0652: Sorting or classification of particles or molecules
- B01L 2200/10: Integrating sample preparation and analysis in single entity, e.g. lab-on-a-chip concept
- B01L 2300/0627: Sensor or part of a sensor is integrated
- B01L 2300/12: Specific details about materials
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2795/10221: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2795/10243: viral genome or elements thereof as genetic vector
- C12N 2795/10251: Methods of production or purification of viral material
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- B01L: CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present disclosure provides methods and kits for generating recombinant bacteriophage genomes.

## Claims

### Claim 1

A method for generating a recombinant bacteriophage genome comprising:
(a) contacting a non-recombinant bacteriophage genome with a sgRNA-CRISPR enzyme conjugate in vitro under conditions where
the sgRNA-CRISPR enzyme conjugate cleaves a protospacer sequence within the non-recombinant bacteriophage genome to produce a cleaved non-recombinant bacteriophage genome; and
(b) recombining in vitro the cleaved non-recombinant bacteriophage genome with a heterologous nucleic acid in the presence of a recombination system under conditions to produce a recombinant bacteriophage genome.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cleaved non-recombinant bacteriophage genome comprises a first cleaved bacteriophage genomic fragment and a second cleaved bacteriophage genomic fragment.

### Claim 3 (depends on 2)

The method of claim 2, wherein the heterologous nucleic acid comprises a 5′ flanking region that is homologous to the 3′ end of the first cleaved bacteriophage genomic fragment, and a 3′ flanking region that is homologous to the 5′ end of the second cleaved bacteriophage genomic fragment.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, further comprising propagating the recombinant bacteriophage genome in a bacterial host.

### Claim 5 (depends on 4)

The method of claim 4, wherein the bacterial host is a non-natural bacterial host cell.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the CRISPR enzyme is a Cas protein selected from the group consisting of Cast, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9, Cas10, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, and Csf4.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the protospacer sequence is 5′ GCTTACGCAGAAGATGCAGA 3′ (SEQ ID NO: 5).

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the non-recombinant bacteriophage genome corresponds to K1-5 phage.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the nucleic acid sequence of the recombinant bacteriophage genome comprises SEQ ID NO: 3.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9, wherein the nucleic acid sequence of the recombinant bacteriophage genome comprises SEQ ID NO: 4.

### Claim 11

A method for generating a recombinant bacteriophage genome comprising:
(a) contacting a non-recombinant bacteriophage genome comprising a single first recognition site with a first restriction enzyme in vitro under conditions where the first restriction enzyme cleaves the first recognition site to produce a cleaved non-recombinant bacteriophage genome; and
(b) recombining in vitro the cleaved non-recombinant bacteriophage genome with a heterologous nucleic acid in the presence of a recombination system under conditions to produce a recombinant bacteriophage genome.

### Claim 12 (depends on 11)

The method of claim 11, wherein the cleaved non-recombinant bacteriophage genome comprises a first cleaved bacteriophage genomic fragment and a second cleaved bacteriophage genomic fragment.

### Claim 13 (depends on 12)

The method of claim 12, wherein the heterologous nucleic acid comprises a 5′ flanking region that is homologous to the 3′ end of the first cleaved bacteriophage genomic fragment, and a 3′ flanking region that is homologous to the 5′ end of the second cleaved bacteriophage genomic fragment.

### Claim 14 (depends on 11, 12, 13)

The method of any one of claims 11-13, wherein the non-recombinant bacteriophage genome corresponds to E. coli T7.

### Claim 15 (depends on 11, 12, 13, 14)

The method of any one of claims 11-14, further comprising propagating the recombinant bacteriophage genome in a bacterial host cell.

### Claim 16 (depends on 15)

The method of claim 15, wherein the bacterial host cell is a natural bacterial host cell.

### Claim 17 (depends on 11, 12, 13, 14, 15, 16)

The method of any one of claims 11-16, wherein the first restriction enzyme is SwaI.

### Claim 18 (depends on 11, 12, 13, 14, 15, 16)

The method of any one of claims 11-16, wherein the first restriction enzyme is NheI.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, wherein the heterologous nucleic acid is about 500-1050 base pairs in length.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 1-19, wherein the recombination system comprises a 5′-3′ exonuclease, a DNA polymerase, and a DNA ligase.

### Claim 21

A method for generating a recombinant bacteriophage genome comprising:
(a) contacting a non-recombinant bacteriophage genome with
(i) a sgRNA-CRISPR enzyme conjugate in vitro under conditions where the sgRNA-CRISPR enzyme conjugate cleaves a protospacer sequence within the non-recombinant bacteriophage genome to produce a cleaved non-recombinant bacteriophage genome; or
(ii) a restriction enzyme in vitro under conditions where the restriction enzyme cleaves a unique recognition site within the non-recombinant bacteriophage genome to produce a cleaved non-recombinant bacteriophage genome;
(b) transforming the cleaved non-recombinant bacteriophage genome into a bacterial host cell, wherein the bacterial host cell comprises a vector that expresses a heterologous nucleic acid; and
(c) recombining in vivo the cleaved non-recombinant bacteriophage genome with the heterologous nucleic acid in the presence of a non-endogenous recombination system under conditions to produce a recombinant bacteriophage genome.

### Claim 22 (depends on 21)

The method of claim 21, wherein the cleaved non-recombinant bacteriophage genome comprises a first cleaved bacteriophage genomic fragment and a second cleaved bacteriophage genomic fragment.

### Claim 23 (depends on 22)

The method of claim 22, wherein the heterologous nucleic acid comprises a 5′ flanking region that is homologous to the 3′ end of the first cleaved bacteriophage genomic fragment, and a 3′ flanking region that is homologous to the 5′ end of the second cleaved bacteriophage genomic fragment.

### Claim 24 (depends on 21, 22, 23)

The method of any one of claims 21-23, wherein the CRISPR enzyme is a Cas protein selected from the group consisting of Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9, Cas10, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, and Csf4.

### Claim 25 (depends on 21, 22, 23)

The method of any one of claims 21-23, wherein the restriction enzyme is AclI, HindIII, SspI, MluCI Tsp509I, PciI, AgeI, BspMI, BfuAI, SexAI, MluI, BceAI, HpyCH4IV, HpyCH4III, BaeI, BsaXI, AflIII, SpeI, BsrI, BmrI, BglII, AfeI, AluI, StuI, ScaI, ClaI, BspDI, PI-SceI, NsiI, AseI, SwaI, CspCI, MfeI, BssSI, BssSαI, Nb.BssSI, BmgBI, PmlI, DraIII, AleI, EcoP15I, PvuII, AlwNI, BtsIMutI, TspRI, NdeI, NlaIII, CviAII, FatI, MslI, FspEI, XcmI, BstXI, PflMI, BccI, NcoI, BseYI, FauI, SmaI, XmaI, TspMI, Nt.CviPII, LpnPI, AciI, SacII, BsrBI, MspI, HpaII, ScrFI, BssKI, StyD4I, BsaJI, BslI, BtgI, NciI, AvrII, MnlI, BbvCI, Nb.BbvCI, Nt.BbvCI, SbfI, Bpu10I, Bsu36I, EcoNI, HpyAV, BstNI, PspGI, StyI, BcgI, PvuI, BstUI, EagI, RsrII, BsiEI, BsiWI, BsmBI, Hpy99I, MspA1I, MspJI, SgrAI, BfaI, BspCNI, XhoI, PaeR7I, TliI, EarI, AcuI, PstI, BpmI, DdeI, SfcI, AflII, BpuEI, SmlI, AvaI, BsoBI, MboII, BbsI, XmnI, BsmI, Nb.BsmI, EcoRI, HgaI, AatII, ZraI, Tth111I, PflFI, PshAI, AhdI, DrdI, Eco53kI, SacI, BseRI, PleI, Nt.BstNBI, MlyI, HinfI, EcoRV, MboI, Sau3AI, DpnII, BfuCI, DpnI, BsaBI, TfiI, BsrDI, Nb.BsrDI, BbvI, BtsI, BtsαI, Nb.BtsI, BstAPI, SfaNI, SphI, SrfI, NmeAIII, NaeI, NgoMIV, BglI, AsiSI, BtgZI, HinP1I, HhaI, BssHII, NotI, Fnu4HI, Cac8I, MwoI, NheI, BmtI, SapI, BspQI, Nt.BspQI, BlpI, TseI, ApeKI, Bsp1286I, AlwI, Nt.AlwI, BamHI, FokI, BtsCI, HaeIII, PhoI, FseI, SfiI, NarI, KasI, SfoI, PluTI, AscI, EciI, BsmFI, ApaI, PspOMI, Sau96I, NlaIV, KpnI, Acc65I, BsaI, HphI, BstEII, AvaII, BanI, BaeGI, BsaHI, BanII, RsaI, CviQI, BstZ17I, BciVI, SalI, Nt.BsmAI, BsmAI, BcoDI, ApaLI, BsgI, AccI, Hpyl66II, Tsp45I, HpaI, PmeI, HincII, BsiHKAI, ApoI, NspI, BsrFI, BsrFαI, BstYI, HaeII, CviKI-1, EcoO109I, PpuMI, I-CeuI, SnaBI, I-SceI, BspHI, BspEI, MmeI, TaqαI, NruI, Hpy188I, Hpy188III, XbaI, BclI, HpyCH4V, FspI, PI-PspI, MscI, BsrGI, MseI, Pad, PsiI, BstBI, DraI, PspXI, BsaWI, BsaAI, and EaeI.

### Claim 26

A method for generating a recombinant bacteriophage genome comprising:
(a) transforming an intact non-recombinant bacteriophage genome into a bacterial host cell, wherein the bacterial host cell comprises a vector that expresses a heterologous nucleic acid; and
(b) recombining in vivo the intact non-recombinant bacteriophage genome with the heterologous nucleic acid in the presence of a non-endogenous recombination system under conditions to produce a recombinant bacteriophage genome.

### Claim 27 (depends on 26)

The method of claim 26, wherein the heterologous nucleic acid comprises
(a) a 5′ flanking region that is homologous to a first region within the intact non-recombinant bacteriophage genome; and
(b) a 3′ flanking region that is homologous to a second region within the intact non-recombinant bacteriophage genome, wherein the first region of the intact non-recombinant bacteriophage genome is located 5′ to the second region of the intact non-recombinant bacteriophage genome.

### Claim 28 (depends on 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 21-27, wherein the bacterial host cell is a non-natural bacterial host cell or a natural bacterial host cell.

### Claim 29 (depends on 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 21-28, wherein the non-endogenous recombination system is induced in the bacterial host cell.

### Claim 30 (depends on 29)

The method of claim 29, wherein the non-endogenous recombination system is induced by the addition of arabinose.

### Claim 31 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 21-30, wherein the non-endogenous recombination system comprises lambda Red proteins Gam, Exo, and Beta operably linked to an inducible promoter.

### Claim 32 (depends on 31)

The method of claim 31, wherein the inducible promoter is araB.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 1-8 or 11-32, wherein the heterologous nucleic acid comprises an open reading frame that encodes a bioluminescent protein, a fluorescent protein, a chemiluminescent protein, or any combination thereof.

### Claim 34 (depends on 33)

The method of claim 33, wherein the open reading frame of the heterologous nucleic acid is operably linked to an expression control sequence that is capable of directing expression of the bioluminescent protein, the fluorescent protein, the chemiluminescent protein, or any combination thereof.

### Claim 35 (depends on 33, 34)

The method of claim 33 or 34, wherein the bioluminescent protein is Aequorin, firefly luciferase, Renilla luciferase, red luciferase, luxAB, or nanoluciferase.

### Claim 36 (depends on 33, 34)

The method of claim 33 or 34, wherein the chemiluminescent protein is (3-galactosidase, horseradish peroxidase (HRP), or alkaline phosphatase.

### Claim 37 (depends on 33, 34)

The method of claim 33 or 34, wherein the fluorescent protein is TagBFP, Azurite, EBFP2, mKalamal, Sirius, Sapphire, T-Sapphire, ECFP, Cerulean, SCFP3A, mTurquoise, monomeric Midoriishi-Cyan, TagCFP, mTFP1, EGFP, Emerald, Superfolder GFP, Monomeric Azami Green, TagGFP2, mUKG, mWasabi, EYFP, Citrine, Venus, SYFP2, TagYFP, Monomeric Kusabira-Orange, mKOκ, mKO2, mOrange, mOrange2, mRaspberry, mCherry, dsRed, mStrawberry, mTangerine, tdTomato, TagRFP, TagRFP-T, mApple, mRuby, mPlum, HcRed-Tandem, mKate2, mNeptune, NirFP, TagRFP657, IFP1.4, iRFP, mKeima Red, LSS-mKate1, LSS-mKate2, PA-GFP, PAmCherryl, PATagRFP, Kaede (green), Kaede (red), KikGR1 (green), KikGR1 (red), PS-CFP2, PS-CFP2, mEos2 (green), mEos2 (red), PSmOrange, or Dronpa.

### Claim 38 (depends on 34, 35, 36, 37)

The method of any one of claims 34-37, wherein the expression control sequence is an inducible promoter or a constitutive promoter.

### Claim 39 (depends on 6)

The method of claim 6, wherein the CRISPR enzyme is Cas9.

### Claim 40 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 11-26, wherein the nucleic acid sequence of the recombinant bacteriophage genome comprises SEQ ID NO: 2.

### Claim 41 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 11-26, wherein the nucleic acid sequence of the recombinant bacteriophage genome comprises SEQ ID NO: 1.

### Claim 42 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 11-26, wherein the nucleic acid sequence of the recombinant bacteriophage genome comprises one or more of SEQ ID NO: 6 or SEQ ID NO: 7.
